首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2015年 10期 胆汁淤积和胆道疾病 => 胆汁淤积和胆道疾病 =>非诺贝特辅助治疗原发..
非诺贝特辅助治疗原发性胆汁性肝硬化疗效的Meta分析
Efficacy of adjuvant therapy with fenofibrate for primary biliary cirrhosis: a Meta-analysis
文章发布日期:2015年09月07日  来源:  作者:俞媛,杨宗国,陈姼姼,等  点击次数:2307次  下载次数:501次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的对非诺贝特辅助治疗原发性胆汁性肝硬化(PBC)患者的有效性进行系统评估。方法检索中国知网、万方、中国生物医学文献数据库、Pubmed、Embase及Cochrane library数据库中自建库至2014年12月31日间发表的相关随机对照试验(RCT),对纳入的文献进行资料提取和质量评价,采用Stata10.1软件对数据进行统计分析。若具有同质性则选择固定效应模型分析,有异质性则选择随机效应模型。结果共纳入6篇RCT进行分析。结果显示:辅助使用非诺贝特治疗后,PBC患者的GGT、ALT、ALP水平较治疗前明显下降(标准化均数差分别为-1.595、-0.447、-2.124,P值均<0.05);而AST、TBil水平在干预前后差异无统计学意义(P值均>0.05)。在改善免疫球蛋白M方面,非诺贝特辅助治疗前后差异无统计学意义(P>0.05)。结论基于当前证据,非诺贝特辅助治疗PBC可以有效改善患者肝功能,但是并不能有效改善患者的免疫功能。本文样本量较少,尚需要更多大样本、多中心、高质量的RCT进行验证。
【Abstract】:ObjectiveTo assess the efficacy of adjuvant therapy with fenofibrate for primary biliary cirrhosis (PBC). MethodsCNKI, Wanfang Data, China Biology Medicine, PubMed, Embase, and Cochrane library were searched for the pertinent literature of randomized controlled trials (RCTs) of adjuvant therapy with fenofibrate for PBC published up to December 31, 2014. Data extraction and quality assessment were carried out, and the data were statistically analyzed by Stata10.1 software. Respectively, for heterogeneity test. The fixed effect model is chosen for homogeneity, and the random effect model is chosen for heterogeneity. ResultsSix RCTs met the inclusion criteria. Treatment with fenofibrate was associated with significantly reduced levels of gamma-glutamyl transpeptidase, alanine aminotransferase, and alkaline phosphatase in PBC patients (SMD=-1.595, -0.447, and -2.125, respectively, all P<0.05). There were no significant changes in the levels of aspartate aminotransferase and total bilirubin after adjuvant therapy with fenofibrate (both P>0.05). Also, fenofibrate led to no significant improvement in immunoglobulin M (P>0.05). ConclusionFenofibrate, which improves the indicators of liver function but leads to no changes in immunological indicators, appears to be an effective adjuvant therapy in PBC patients. There is a critical need for more large-scale, multi-center, high-quality RCTs to determine its effect on liver disease-related morbidity and mortality.
【关键字】:肝硬化,胆汁性;普鲁脂芬;Meta分析
【Key words】:liver cirrhosis, biliary; procetofen; Meta-analysis
【引证本文】:俞媛, 杨宗国, 陈姼姼, 等. 非诺贝特辅助治疗原发性胆汁性肝硬化疗效的Meta分析[J]. 临床肝胆病杂志, 2015, 31(10): 1630-1633.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号